Professor Evis Sala
Personal home page: http://radiology.medschl.cam.ac.uk/about-us/departmental-staff/academic-staff/professor-evis-sala/
PubMed journal articles - click here
Professor Evis Sala is pleased to consider applications from prospective PhD students.
My research focuses on integrated diagnostics, through the clinical development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging. My research in the new field of “radio genomics” has focused on understanding the molecular basis of cancer by demonstrating the phenotypic patterns which occur as a result of multiple genetic alterations that interact with the tumour microenvironment to drive the disease. My work integrates quantitative imaging methods for evaluation of spatial and temporal tumour heterogeneity with genomics, proteomics and metabolomics. The integration of “multi-omics” data will be essential for unravelling tumour heterogeneity and making real-time clinical decisions for patients.
Symplectic Elements feed provided by Research Information, University of Cambridge
•Sala E, Kataoka MY, Priest AN, Gill AB, McClean MA, Joubert I, Graves MJ, Crawford R, Jimenez-Linan M, Earl H, Hodgkin C, Griffiths JR, Lomas DJ, Brenton JD. Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. Radiology 2012 Apr; 263(1):149-159.
•Vargas HA, Micco M, Hong S, Goldman DA, Dao, F, Weigelt B, Soslow RA, Hricak H, Levine DA, Sala E. Association between morphologic computed tomography imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: A Hypothesis Generating Study. Radiology. 2015 Mar; 274(3):742-51
•Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, Nougaret S, Sosa RE, Vargas HA, Soslow R, Hricak H, Abu-Rustum NR, Sala E. Differentiation of Uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and role of texture analysis. Eur Radiol 2016 PMID: 27921159 DOI:10.1007/s00330-016-4623-9.
•Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, Hosking K, Gounaris I, Jimenez-Linan M, Earl HE, Qian W, Rosenfeld N, Brenton JD. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective analysis. PLoS Med 2016 Dec 20;13(12):e1002198. doi:10.1371/journal.pmed.1002198.
•Jiménez-Sánchez A, Memmon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok J, Sala E, Merghoub T, Snyder A, Miller ML. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 2017;170(5):927-938.e920
•Nougaret, S., Lakhman, Y., Molinari, N., Feier, D., Scelzo, C., Vargas, H. A., … Sala, E. (2018). CT features of ovarian tumors: Defning key differences between serous borderline tumors and low-grade serous carcinomas. American Journal of Roentgenology, 210(4), 918–926.